Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Overview of attention for article published in Experimental Hematology & Oncology, April 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 36 Dimensions

Readers on

mendeley: 52 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 3,735 followers.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose https://t.co/zeydNyfmA8

02 Jun 2019

Reply Repost Favourite

RT @Allergy_bio: Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose: Patients with Myelod…

31 May 2019

Reply Repost Favourite

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose: Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating… htt

30 May 2019

Reply Repost Favourite

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. https://t.co/cGH27ue8xV

25 Apr 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.